Hybrid Pharmaceutical, The Genomics Biotech Engineering Company, announced Barron Graham’s –Join Hybrid GenNxeix Inc as Chief Information Officer

Houston, TX – November 01, 2011 - - (BUSINESS WIRE) ----- Hybrid Pharmaceutical, the Genomics Biotech Engineering company, today announced that Barron Graham’s – Graham is to join Hybrid GenNxeix Inc. (GenNxeix) as a Biotech Consulting Partner effective November 1, 2011. Barron will work directly with the Vice President of Worldwide Marketing in developing strategic marketing, branding, communications and sales initiatives for Hybrid GenNxeix ®. Mr. Graham bring more than 28years of expertise in brand management, business planning, advertising, digital, integrated communications, direct marketing, promotions, research and sales & marketing.

Barron brings a breath of experience and strong track record of leadership in successfully building brands and pioneering new markets,” said Rose Conrad Ph.D., Chief Executive Officer of Hybrid Pharmaceutical.
“His years of experience in developing go-to-market strategies, his intelligence and his excitement to become part of Hybrid GenNxeix is evident that Barron’s direction and steward of the GenNxeix brand will help to strengthen and solidify our market leadership position,” she said.



Hybrid GenNxeix a new subsidiary of Hybrid Pharma, is committed to being the world’s premiere Medical Informatics and Medical Services Companies. As a leader in genomic trials, healthcare IT, scientist electronic GenNxeix, development and manufacturing of biologics, the company offers a suite of products and services. Products and services include DNA paternity testing, Genomics analysis and testing, BioGenetic research and samples and Regenerative medicine.

As an entrepreneur for more than 28 years, Barron Graham’s unique qualifications in Business Establishment, Business Development and Marketing makes him highly capable and much sought after in the business world. His experience and expertise came from across section of industries namely: Real Estate, Investment Banking, Telecoms Retail, Business Financing, Insurance, Merchant Services, Network Marketing and Business Establishment & Development. In which he is personally starting more than 100 companies in several countries.


This press release contains forward-looking statements, including statements relating to the expected demand for Hybrid Pharma's products and services, statements regarding Hybrid Pharma’s growth and market opportunities, and statements relating to Hybrid Pharma’s ability to meet the needs of distributed organizations. These forward-looking statements involve risks and uncertainties, as well as assumptions that, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Hybrid Pharma reserves the right to modify future product plans at any time.
About Hybrid Pharma

Hybrid Pharma is a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services is available at GenNxeix.

“As you look around, you’ll see that medicine has changed dramatically. There is a huge Genomic shift occurring. The Genomicst has completely redefined the world’s economy and has created evidence base Medicine. If you are in medicine today and you are not using Genomics Science o, you will be left behind.”

20% Of Breast Cancers IS HER2 over-expressed. HER2 Gene Amplified Has A 82% Chance of Relapses

Robert Graham and Hybrid Medical Media Reporting from University of Texas Houston October, 2011-------

20% Of Breast Cancers are HER2 is over-expressed. HER2 Gene Amplified in Breast Cancer 82% Chance of Relapse. 34% chance of relapse when Using HybridNxeix Scr Kinase inhibitor with Treatment.
Results from an earlier analysis of the HERA trial, the 4-year follow-up results do not show a statistically significant difference in overall survival when not taking Using HybridNxeix Scr Kinase inhibitor with Treatment.
Again HER2-positive cancers, which make up about 20 percent of all breast cancers, are more aggressive and women with this form of breast cancer have a higher risk of disease recurrence and death. Most Patients take Trastuzumab to extend survival of women with HER2-overexpressing metastatic breast .
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation—functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and, among other effects, causes breast cells to reproduce uncontrollably
HybridNxeix study 61 cases of breast carcinoma with well-documented amplification of the human epidermal growth factor receptor-2 gene and corresponding banked fresh-frozen tissue were identified and divided into two separate groups based on whether they received trastuzumab or not. The first group consisted of 12 patients who had received trastuzumab in the adjuvant setting, of which three later experienced tumor recurrence. The second group consisted of 10 patients not treated with trastuzumab, of which 6 were later found to have recurrence. Differentially expressed genetic profiles were determined using human genome-wide Illumina Bead Microarrays. The differentially expressed genes for non-recurrence vs recurrence in the trastuzumab-treated group were distinct from those in the same comparison group in the untreated group. Differential expression of key genes indentified in this study might offer an insight into a possible mechanism of trastuzumab resistance in breast carcinoma, and may emerge as potential predictive biomarkers indicative of trastuzumab resistance.
science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.

The better News is that Genomics is on the Clock.


Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.
formalin fixed, paraffin embedded techniques and Her-2 Approximately Where do you really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Breast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.
The better News is that Genomics is on the Clock.

Genomics provide a faster cheaper more effective way to detect
the Her2 gene by using Semiconductor Sequencing. A example of
this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA ohttp://www.blogger.com/img/blank.gifr RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.

Where do we really come from And how can this information help solve Breast Cancer

Robert Graham and Hybrid Medical Media Reporting from University of Texas Galveston September 6, 2011-------
Where do we really come from And how can this information help solve Breast Cancer
Where do we really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Brhttp://www.blogger.com/img/blank.gifeast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2

The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.

The better News is that Genomics is on the Clock.

Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.
formalin fixed, paraffin embedded techniques and Her-2 Approximately Where do you really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Breast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array.
The better News is that Genomics is on the Clock.

Genomics provide a faster cheaper more effective way to detect
the Her2 gene by using Semiconductor Sequencing. A example of
this technique is Hybrid Pharma Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.

A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA ohttp://www.blogger.com/img/blank.gifr RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments.

Hybrid Pharma uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips.

Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA
by a polymerase, a hydrogen ion is released.

Hybrid Pharma used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.

HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.

Hybrid Medical Media Covers this years Cadillac Simon Fashion Show

Robert Graham and Hybrid Medical Media Reporting from Houston Galleria Simon Fashion Show September 8, 2011


Why Hybrid GenConnect opened a Office in Houston
One Reason is that Houston has grown in Culture and Style
Hybrid Medical Media Cover this years Cadillac Simon Fashion Show.

Cadillac has been part of the Simon Fashion
NOW series since its appearance in Houston.
With artful design and precision performance,
Cadillac is a celebration of spring fashion trends.

As a part of this year’s fashion extravaganza,
Cadillac is at the forefront of art and design with
a new interactive style stop.

What is Better Than a Mammogram and can Help The Obama Administration Create 4 Million Jobs

What is Better Than a Mammogram and can Help The Obama Administration Create 4 Million Jobs
Robert Graham and Hybrid Medical Media Reporting from Rice University September 6, 2011

What is Genomics? Genomics is a new and fast expanding area of biology encompassing high throughput or large scale experimentation at the whole genome level, and the organization, analysis and interpretation of the huge amount of data emerging from genome projects. Major new technologies have evolved recently that enable experimentation at the whole genome level, and more novel technologies are currently being developed. This volume describes in detail the new technology necessary to study the entire genome in a holistic manner and all the high throughput and large-scale experimental methodologies currently being used in genomic science. In addition the authors describe the progress of the newest technologies that are currently being developed. Written by experts in the field, this concise yet informative volume covers all aspects of technology pertaining to genomic studies. It is an essential book for anyone involved in genomic science.


Breast Cancer patients can aligning environmental science with regulation, Genomics in Regulatory Ecotoxicology: Applications and Challenges presents the first in-depth set of recommendations published in the open literature focused specifically on how genomics data could be used in regulatory ecotoxicology. The book develops a conceptual framework of how genomics data can most effectively impact current approaches for ecological risk assessments. It also identifies biomarkers of exposure and effects for both lab and field monitoring studies and provides a basis for the extrapolation of chemical effects across species. It explores exactly how data generated from new genomics technologies might impact or benefit risk assessment. Features: Identifies biomarkers of exposure and effects for use in both lab and field studies, Provides a basis for the extrapolation of chemical effects across species, Describes current and planned applications of genomic technologies to screening assays for use in ecotoxicology decision-making, including risk assessment, Focuses on the development and application of genomics to tiered testing, including how genomics may be used to support streamlining of current chemical testing programs, Highlights the application of genomic technologies to complex mixtures of contaminants in the environment, such as sites requiring remediation.
Breast Cancer Genomics in Regulatory Ecotoxicology: Applications and Challenges is one of many SETAC publications that offer timely, innovative, and critically reviewed perspectives on current topics relating to broad environmental toxicology and chemistry issues. SETAC assumes an active leadership in the development of educational programs and publishes the peer-reviewed, international journals Environmental Toxicology and Chemistry and Integrated Environmental Assessment and Management.

GenC has new technology to systematically quantify proteins within a small sample by coupling antibody-mediated protein binding with qPCR quantification. The assay probes are target-specific antibodies that are conjugated to two different oligonucleotides through a biotin-streptavidin linkage. When the antibodies bind their target, the oligos come in proximity of each other. Addition of a connector oligonucleotide and DNA ligase creates a DNA amplicon, which is amplified in a qPCR reaction. The qPCR results correlate with the amount of protein in a sample.

Often these are analyzed using immunohistochemistry, but that is much more labor intensive and much less quantitative. Thus, studies now can be conducted with greater ease and throughput with actual tumors. This will allow a better understanding of the protein profiles of cancers, and thus potentially identify new therapeutic biomarkers.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.

GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

Hybrid GenConnect will Reduce Breast Cancer by 5 percentage points by 2014

Personalized Medicine in The Black community -Message to Martin Luther King Jr. Foundation

August 28th, 2011 By Robert Graham Reporting from Baylor College of Medicine Houston Texas -----< Business--Wire>


The State of Genomics and Personalized Medicine in The Black community -Message to Martin Luther King Jr. Foundation

Public Health Genomics (PHG) at the National Cancer Institute promotes the integration of genomics and personalized medicine into public health cancer research, policy, and control to reduce the burden of cancer in the United States and around the world.

Hybrid GenConnect Purpose in Genomic Science is to Draw from Organizational Theory and existing body of work about science. Hybrid seeks to operationalize a Model to represent empirical evidence that draws on Quanative mapping of Breast
Cancer

18% of Black Women get Breast Cancer to 7% of White Women, what can we do to reduce the Breast Cancer rate in the Black Community. GenConnect located in Houston at the University of Texas Medical Center research area. Suggested that more research be used using real-time polymerase chain reaction, also called quantitative real time polymerase chain reaction (Q-PCR/qPCR/qrt-PCR) or kinetic polymerase chain reaction (KPCR), is a laboratory technique based on the PCR, which is used to amplify and simultaneously quantify a targeted DNA molecule. A long with Nanoparticles which has the potential to enable breast cancer research and improve molecular imaging, early detection, prevention, and treatment of breast cancer for Black Women.
GenConnect offers both absolute and relative quantitation using calibration curves and a choice of normalization strategies. Full validation to ICH guidelines is available to support the analysis of transcript biomarkers as part of a clinical trial.

GenC has new technology to systematically quantify proteins within a small sample by coupling antibody-mediated protein binding with qPCR quantification. The assay probes are target-specific antibodies that are conjugated to two different oligonucleotides through a biotin-streptavidin linkage. When the antibodies bind their target, the oligos come in proximity of each other. Addition of a connector oligonucleotide and DNA ligase creates a DNA amplicon, which is amplified in a qPCR reaction. The qPCR results correlate with the amount of protein in a sample.

Often these are analyzed using immunohistochemistry, but that is much more labor intensive and much less quantitative. Thus, studies now can be conducted with greater ease and throughput with actual tumors. This will allow a better understanding of the protein profiles of cancers, and thus potentially identify new therapeutic biomarkers.

A nanometer is a billionth of a meter. It's difficult to imagine anything so small, but think of something only 1/80,000 the width of a human hair. Ten hydrogen atoms could be laid side-by-side in a single nanometer.

GenConnect minuscule molecule that will be used to detect breast cancer is a quantum dot. Quantum dots are tiny crystals that glow when they are stimulated by ultraviolet light. The wavelength, or color, of the light depends on the size of the crystal. Latex beads filled with these crystals can be designed to bind to specific DNA sequences.

Hybrid GenConnect will Reduce Breast Cancer by 5 percentage points by 2014

Genomics and Gastric bypass surgery -- decreases the incidence of Breast Cancer by 80%

July 14, 2011 By Robert Graham Reporting from Baylor College of Medicine Houston Texas -----< Business--Wire>

Genomics and Gastric bypass surgery -- decreases the incidence of Breast Cancer by 80%

Gastric bypass procedures (GBP) is operations that divides the stomach into a small upper pouch and a much larger lower "remnant" pouch and then re-arranges the small intestine to allow both pouches to stay connected to it. Surgeons have developed several different ways to reconnect the intestine, thus leading to several different GBP names. Any GBP leads to a marked reduction in the functional volume of the stomach, accompanied by an altered physiological and physical response to food
Hybrid GenConnect Inc estimated 908,000 people in the U.S. had gastric bypass, gastric banding , or some other form of bariatric.


Candidates for bariatric surgery include those who are morbidly obese, which for most people means being 100 or more pounds overweight or having a body mass index (BMI) of 40 or more.

A 5-foot, 8 -inch person who weighs 250 or more would be considered morbidly obese, as would someone who is 6 feet tall and weighs at least 295 pounds.

Hybrid GenConnect Inc and others studied 900,000 adults followed for 16 years, Calle, et al, found the death rate from cancer was increased by 52 percent in men and 62 percent in women when the initial BMI was 40 or more. Cancers of the esophagus, colon and rectum, liver, gall bladder, pancreas, kidney, non-Hodgkins lymphoma and multiple myeloma were increased in both men and women. Stomach and prostate cancer was increased in men. Breast, uterus, cervix and ovary cancer were increased in women. They estimated, on the basis of this study, that overweight and obesity could account for 14 percent of all cancer deaths in the United States in men and 20 percent in women.
The newly reported study included 1,035 morbidly obese patients who underwent bariatric surgery between 1986 and 2002 and 5,746 patients matched for age, gender, and duration of morbid obesity who did not have surgery.

During five years of follow-up, 21 (2%) surgically treated patients were diagnosed with cancer, compared to 487 (8.5%) of nonsurgically treated patients.

The bariatric surgery patients had an 85% lower incidence of breast cancer, a 70% lower incidence of colon and pancreatic cancer, a 50% lower incidence of non-Hodgkin's lymphoma, and a 60% lower incidence of skin cancer
Adding years to your life after being Diagnosed with breast cancer is to take a breast cancer test using semiconductor sequencing to find P53,P63,BRCA1 and BRCA2 the major genes related to hereditary breast cancer. Women who have inherited certain mutations in these genes have a high risk of developing breast cancer, ovarian cancer, and several other types of cancer during their lifetime.

Hybrid GenConnect breast cancer Assay is a unique diagnostic tests
that can help patients and their doctors make informed,
individualized treatment decisions.

The American Society of Clinical Oncology® (ASCO®) and the
National Comprehensive Cancer Network® (NCCN®) have
included that genomics assay in their guidelines as an option
to predict whether certain patients will benefit from different
Therapies.